Association of SGLT-2 Inhibitor Use with Wound Healing and Amputation Risk in Patients with Diabetic Foot Ulcers: A Prospective Observational Study

Aim: The extant literature contains conflicting findings with regard to the safety of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) in patients with diabetic foot ulcers (DFUs). The present study aims to evaluate the association between the use of SGLT-2 inhibitors and wound healing outcomes and the risk of amputation in patients diagnosed with type 2 diabetes mellitus (DM) and Wagner stage 1-2 DFU. Methods: This prospective observational study was conducted between March 1, 2023, and August 31, 2024. The study population comprised 208 patients with type 2 DM and Wagner stage 1-2 DFU, all of whom completed six months of follow-up. Patients were grouped according to treatment: metformin plus insulin (n=102) or metformin plus insulin and an SGLT-2 inhibitor (n=106). Clinical, biochemical, wound-healing, and amputation outcomes were compared between groups. Subgroup analyses were performed for users of dapagliflozin and empagliflozin. Associations of SGLT-2 inhibitor use with wound healing and amputation were assessed using ordinal and binary logistic regression, respectively, with multivariable adjustment for relevant baseline differences. Results: No statistically significant differences in wound healing and amputation rates were observed between patients with and without SGLT-2 inhibitor use. In the SGLT-2 inhibitor group, levels of serum albumin were elevated, whereas urinary albumin excretion was reduced (p=0.002 and p<0.001, respectively). No significant differences were observed between patients treated with dapagliflozin and empagliflozin in terms of wound healing or amputation. Conclusion: No clear association has been observed between the use of SGLT-2 inhibitors and impaired wound healing or amputation in patients with DFUs. Further studies with larger sample sizes are needed to clarify these findings.

Authors

Institutions

Publication Details

Journal
Medical Bulletin of Haseki
Published
2026-11-17
DOI
https://doi.org/10.4274/haseki.galenos.2026.25238
Primary Topic
Diabetic Foot Ulcer Assessment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of SGLT-2 Inhibitor Use with Wound Healing and Amputation Risk in Patients with Diabetic Foot Ulcers: A Prospective Observational Study

Tayyibe Saler, Zeynep Gizem Totik, Sevinc Puren Yucel Karakaya
3 links
Medical Bulletin of Haseki
Diabetic Foot Ulcer Assessment and Management
article

Association of SGLT-2 Inhibitor Use with Wound Healing and Amputation Risk in Patients with Diabetic Foot Ulcers: A Prospective Observational Study

Tayyibe Saler, Zeynep Gizem Totik, Sevinc Puren Yucel Karakaya
article en

Abstract

Aim: The extant literature contains conflicting findings with regard to the safety of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) in patients with diabetic foot ulcers (DFUs). The present study aims to evaluate the association between the use of SGLT-2 inhibitors and wound healing outcomes and the risk of amputation in patients diagnosed with type 2 diabetes mellitus (DM) and Wagner stage 1-2 DFU. Methods: This prospective observational study was conducted between March 1, 2023, and August 31, 2024. The study population comprised 208 patients with type 2 DM and Wagner stage 1-2 DFU, all of whom completed six months of follow-up. Patients were grouped according to treatment: metformin plus insulin (n=102) or metformin plus insulin and an SGLT-2 inhibitor (n=106). Clinical, biochemical, wound-healing, and amputation outcomes were compared between groups. Subgroup analyses were performed for users of dapagliflozin and empagliflozin. Associations of SGLT-2 inhibitor use with wound healing and amputation were assessed using ordinal and binary logistic regression, respectively, with multivariable adjustment for relevant baseline differences. Results: No statistically significant differences in wound healing and amputation rates were observed between patients with and without SGLT-2 inhibitor use. In the SGLT-2 inhibitor group, levels of serum albumin were elevated, whereas urinary albumin excretion was reduced (p=0.002 and p<0.001, respectively). No significant differences were observed between patients treated with dapagliflozin and empagliflozin in terms of wound healing or amputation. Conclusion: No clear association has been observed between the use of SGLT-2 inhibitors and impaired wound healing or amputation in patients with DFUs. Further studies with larger sample sizes are needed to clarify these findings.

Medical Bulletin of Haseki
Sağlık Bilimleri Üniversitesi (TR), Cukurova University (TR)
Good health and well-being
Diabetic Foot Ulcer Assessment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon